Posted on 10/03/2010 in Pharmacy Supplier News Teva has selected Dr Phillip Frost as the new permanent chairman of its board of directors.
Dr Frost, who previously served as the board's vice-chairman, takes over from interim chairman Professor Moshe Many following the announcement that previous chairman Eli Hurvitz is leaving the company due to health issues.
He steps into this role following a lengthy career in the pharmaceuticals industry which has seen him assume positions at companies such as Ivax, OPKO Health and PROLOR Biotech.
The newly-appointed chairman said: "I am sure that all the members of the board and all Teva's employees join me in wishing Eli a speedy and full recovery."
Professor Many will become Dr Frost's new vice chairman on the reorganised board.
Last week, the pharmaceutical company launched a generic version of losartan, a hypertension drug formerly sold by Merck Sharpe and Dohme under the name Cozaar, in the UK market.Other news stories from 10/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
